rebel Financial rebel Financial
← All Posts
KIN

Kiniksa Pharmaceuticals International, plc

May 30, 2026 • Author: Phil Ratcliff
Item Proposal Vote
1 Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association.
1a Stephen R. Biggar ✓ For
1b G. Bradley Cole ✓ For
1c Barry D. Quart ✓ For
2 To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company’s UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders. ✓ For
3 To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2026. ✓ For
4 To authorize the Company’s Board of Directors, through its Audit Committee, to determine PwC's remuneration in its capacity as our UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders. ✓ For
5 To receive the Company’s UK statutory annual accounts and report for the period ended December 31, 2025. ✓ For
6 To approve, on an advisory (non-binding) basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2025. ✓ For
7 To approve the Company’s UK Statutory Directors’ Remuneration Policy. ✓ For
8 To approve, on an advisory (non-binding) basis, the compensation of our named executive officers. ✓ For
Attachments
📄
KINI_PROXY_STATEMENT.pdf 1.9 MB
📄
KINI_ANNUAL_REPORT_2025.pdf 2.2 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.